Moneycontrol PRO
LAMF
LAMF

Stocks to Watch Today: Ashok Leyland, Dixon Tech, Zydus Lifesciences, ICICI Lombard, HDB Financial, HDFC Life, Jindal Steel, Biocon in focus on 16 July

Stocks to watch, 16 July: Stocks like HDFC Life Insurance Company, HDB Financial Services, ICICI Lombard General Insurance Company, Just Dial, Dixon Technologies, Zydus Lifesciences, Biocon, Jindal Steel & Power, Asston Pharmaceuticals, and Ashok Leyland will be in focus on July 16.
July 16, 2025 / 01:44 IST
Stocks to Watch Today, 16 July

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:

Results Today

Tech Mahindra, ITC Hotels, Angel One, DB Corp, Le Travenues Technology, Kalpataru, Lotus Chocolate Company, L&T Technology Services, and Reliance Industrial Infrastructure will release their quarterly earnings on July 16.

Quarterly Earnings

HDFC Life Insurance Company Q1 (YoY)

Profit grows 14.4% to Rs 546 crore Vs Rs 478

Total APE (annual premium equivalent) increases 12.5% to Rs 3,225 crore Vs Rs 2,866 crore

Retail (individual) APE soars 12.5% to Rs 2,777 crore Vs Rs 2,467 crore

Value of new business (VNB) increases 12.7% to Rs 809 crore Vs Rs 718 crore

VNB margin expands to 25.1% Vs 25%

Assets under management jumps 14.7% to Rs 3.55 lakh crore Vs Rs 3.1 lakh crore

HDB Financial Services Q1 (YoY)

Profit drops 2.4% to Rs 568 crore Vs Rs 582 crore

Net interest income grows 18.3% to Rs 2,092 crore Vs Rs 1,768 crore

Net interest margin expands to 7.7% Vs 7.6%

Gross loans increases 14.3% to Rs 1.09 lakh crore Vs Rs 95,629 crore

Pre-provisioning operating profit zooms 17.2% to Rs 1,402 crore Vs Rs 1,196 crore

Gross NPA jumps to 2.56% Vs 2.26%

Net NPA climbs to 1.11% Vs 0.77%

ICICI Lombard General Insurance Company Q1 (YoY)

Profit zooms 28.7% to Rs 747 crore Vs Rs 580 crore

Gross written premium grows 1.5% to Rs 8,053 crore Vs Rs 7,931 crore

Gross direct premium income increases 0.6% to Rs 7,735 crore Vs Rs 7,688 crore

Net premier earned surges 14% to Rs 5,136 crore Vs Rs 4,503.9 crore

Combined ratio rises to 102.9% Vs 102.3%

Just Dial Q1 (YoY)

Profit rises 13% to Rs 159.6 crore Vs Rs 141.2 crore

Revenue increases 6.2% to Rs 297.9 crore Vs Rs 280.6 crore

EBITDA grows 7.2% to Rs 86.4 crore Vs Rs 80.6 crore

Margin expands 28 bps to 29% Vs 28.7%

Network 18 Media & Investments Q1 (YoY)

News business operating revenue declines 4.9% to Rs 430 crore Vs Rs 453 crore

News business operating EBITDA grows 68.5% to Rs 4 crore Vs Rs 2 crore

Operating EBITDA margin expands to 1% Vs 0.5%

News business operating expense drops 5.3% to Rs 426 crore Vs Rs 450 crore

Stocks to Watch

Dixon Technologies (India)

The company has entered into a binding term sheet with Kunshan Q Tech Microelectronics (India) and its shareholders for the proposed acquisition of a 51% stake in Q Tech India. This move aims to establish collaboration in the manufacturing, sale, and distribution of camera and fingerprint modules for mobile handsets, Internet of Things (IoT) systems, and automotive applications. The acquisition will be executed through a combination of primary and secondary investments by Dixon.

Additionally, Dixon has entered into a binding term sheet with Chongqing Yuhai Precision Manufacturing Co. to form a prospective joint venture in India with a 74:21 ownership ratio. The JV company will focus on the manufacturing of precision components for laptops, mobile phones, IoT, automotive, and other products.

Kotak Mahindra Bank

Phani Shankar has resigned from the position of President and Chief Credit Officer (Senior Management Personnel) of the bank. His resignation will be effective July 21.

Zydus Lifesciences

The company has received final approval from the US Food and Drug Administration (USFDA) for its Celecoxib capsules, which will be available in 50 mg, 100 mg, 200 mg, and 400 mg strengths. Celecoxib is used to treat pain and inflammation caused by various conditions such as arthritis, ankylosing spondylitis, and menstrual pain.

Biocon

Biocon’s subsidiary, Biocon Biologics, has received approval from the US FDA for KIRSTY (Insulin Aspart-xjhz), 100 units/mL, as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).

KIRSTY is a rapid-acting human insulin analog, indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Bajaj Finserv

The Insurance Regulatory and Development Authority of India (IRDAI) has approved the transfer of 26% equity shares held by Allianz SE in its two insurance subsidiaries—Bajaj Allianz General Insurance Company and Bajaj Allianz Life Insurance Company—to Bajaj Finserv, Bajaj Holdings & Investment (promoter), and Jamnalal Sons (promoter group).

Jindal Steel & Power

Mayank Gupta has resigned as Chief Financial Officer of the company, effective July 15, citing personal commitments.

Bulk Deals

MAS Financial Services

Nippon India Mutual Fund acquired an additional 20 lakh shares at Rs 305 per share from Business Excellence Trust III.

As of March 2025, Nippon India MF held a 5.29% stake in MAS Financial.

SME IPO Listing on July 16

Asston Pharmaceuticals

Stocks Trade Ex-Dividend

Tata Consultancy Services

Piramal Pharma

Anant Raj

Avadh Sugar & Energy

B&A Packaging India

DJ Mediaprint & Logistics

TCI Express

Ultramarine & Pigments

Stock Trades Ex-Bonus

Ashok Leyland

Stock in F&O ban

Glenmark Pharma

Hindustan Copper

RBL Bank

Disclaimer: MoneyControl is a part of the Network18 group. Network18 is controlled by Independent Media Trust, of which Reliance Industries is the sole beneficiary.
Moneycontrol News
first published: Jul 16, 2025 01:44 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347